ArticleFrontiers in endocrinology2026
An interpretable machine learning model for detecting vision-threatening diabetic retinopathy among patients with diabetic retinopathy: a web-based cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management.Frontiers in endocrinology · 2026Review
- Extreme phenotype-derived machine learning reveals susceptibility and resilience signatures for severe diabetic retinopathy.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vision-threatening diabetic retinopathy (VTDR) is a severe complication of type 2 diabetes mellitus (T2DM), particularly prevalent in patients with prolonged disease duration, poor glycemic control, and systemic comorbidities. This condition frequently progresses asymptomatically toward irreversible blindness without timely intervention. The early identification of VTDR is challenging due to the lack of validated biomarkers and a reliance on subjective clinical assessments. This study aimed to develop and validate an interpretable machine learning (ML) model to detect VTDR among patients with diabetic retinopathy (DR). Methods: Retrospective clinical data from T2DM patients with DR were extracted from the electronic medical records at our hospital and categorized into VTDR and non-VTDR (defined as mild-to-moderate non-proliferative diabetic retinopathy) groups. The dataset was partitioned into training and testing sets (7:3 ratio). Eight ML models were trained and evaluated using metrics such as Area Under the Curve (AUC), accuracy, and recall. Model performance was evaluated using a comprehensive scoring system (total score = 64). Shapley Additive Explanations (SHAP) were used to interpret the best-performing model. A web-based application was developed to demonstrate potential clinical utility. Results: Among 1,124 enrolled patients, the prevalence of VTDR was 36.9%. Key associated factors included diabetic treatment, T2DM duration, glycated hemoglobin levels, albuminuria, and anemia. The Support Vector Machine (SVM) model demonstrated superior performance, with an AUC of 0.879, accuracy of 0.837, precision of 0.833, Brier score of 0.129, and an F1 score of 0.756, outperforming the other ML models. The SVM model achieved the highest total score (57/64) in the testing cohort. Furthermore, decision curve analysis and calibration curves confirmed the robustness and reliability of the models. A simplified calculator derived from the SHAP feature importance rankings maintained strong diagnostic capacity. Conclusion: The interpretable SVM model effectively detected VTDR among patients with DR using routine clinical data. While requiring external validation, this study serves as a proof-of-concept for a cost-effective screening tool that could assist clinicians in prioritizing high-risk patients and facilitating early intervention to prevent irreversible vision impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.